On the recordNovember 16, 2015
FDA's proposal to regulate LDTs is a significant change that would impose considerable new burdens on regulated parties.
Source
congress.govOrrin Hatch: “FDA's proposal to regulate LDTs is a significant change that would impose considerable new burdens on regulated parties.”
Editor's note · Context
Hatch discusses the impact of FDA's proposed regulation on laboratory-developed tests.
Share
More from Orrin Hatch
Sep 25, 2018
I intend to focus this morning on the investigation that was self-initiated by the Department of Commerce under section 232 of the Trade Expansion Act of 1962 to determine whether imports of automobiles and automotive parts threaten to…
Sep 26, 2018
The Congressional Budget Office projects that the PBGC's multiemployer insurance system will exceed resources available to pay claims by $45 billion.
Sep 24, 2018
today I wish to speak about legislation to reauthorize the Emergency Medical Services for Children program administered by the Health Resources and Services Administration's Maternal and Child Health Bureau. I want to thank my fellow bill…
Other voices in this conversation
